NEW YORK, Oct 5 – Irish genomics company HiberGen plans to conduct local population studies in an effort to gain a better understanding of the role SNPs play in diseases such as arthritis, diabetic nephropathy, and pre-eclampsia, HiberGen’s chief scientific officer said Thursday.

HiberGen also announced that an Irish biotech company bought one-third of the company.

“The reason for using the Irish population is because it’s relatively homogenous, which can help to eliminate background noise,” Pat Vaughan told GenomeWeb.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.